Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 3,250 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 3,250 shares of the firm’s stock in a transaction on Thursday, March 27th. The stock was sold at an average price of $21.33, for a total transaction of $69,322.50. Following the completion of the sale, the chief financial officer now directly owns 23,000 shares in the company, valued at approximately $490,590. This trade represents a 12.38 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Benjamin Hohl also recently made the following trade(s):

• On Monday, March 24th, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.50, for a total value of $22,500.00.
• On Thursday, February 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.41, for a total value of $66,332.50.
• On Wednesday, February 5th, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.52, for a total value of $22,520.00.
• On Monday, January 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $21.59, for a total value of $70,167.50.
• On Friday, January 3rd, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.04, for a total transaction of $25,040.00.

Enliven Therapeutics Trading Down 4.1 %

NASDAQ ELVN opened at $18.88 on Wednesday. The stock’s fifty day moving average price is $21.18 and its 200-day moving average price is $23.70. The stock has a market cap of $925.20 million, a P/E ratio of -9.94 and a beta of 1.04. Enliven Therapeutics, Inc. has a 12 month low of $15.96 and a 12 month high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Thursday, March 13th. The company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.07. The firm had revenue of $0.03 million for the quarter. As a group, analysts forecast that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Enliven Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ELVN. Charles Schwab Investment Management Inc. raised its stake in shares of Enliven Therapeutics by 10.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 255,277 shares of the company’s stock worth $6,520,000 after purchasing an additional 24,043 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in Enliven Therapeutics by 25.6% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 17,282 shares of the company’s stock worth $441,000 after buying an additional 3,518 shares during the last quarter. FMR LLC lifted its stake in Enliven Therapeutics by 10.6% during the 3rd quarter. FMR LLC now owns 6,296,179 shares of the company’s stock valued at $160,804,000 after acquiring an additional 601,611 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Enliven Therapeutics by 12.7% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 26,168 shares of the company’s stock valued at $668,000 after acquiring an additional 2,944 shares during the last quarter. Finally, Walleye Capital LLC bought a new stake in shares of Enliven Therapeutics in the third quarter worth approximately $2,539,000. 95.08% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on ELVN. HC Wainwright increased their target price on Enliven Therapeutics from $37.00 to $39.00 and gave the stock a “buy” rating in a research report on Friday, March 21st. BTIG Research initiated coverage on shares of Enliven Therapeutics in a report on Friday, December 13th. They set a “buy” rating and a $42.00 target price on the stock. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $38.75.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.